Clinical practice LCS program finds more disease than NLST

Over a five-year period, a clinical practice lung cancer screening program at Duke University Medical Center in Durham, NC, found more disease than did the National Lung Screening Trial (NLST), researchers have reported. The program showed a higher rate of lung cancer compared to the NLST’s, at 3.4% versus 2.4%. It also found more stage IV disease, wrote a team led by Kyle Lafata, PhD. The results were published April 23 in the Journal of the American College of Radiology. “As LCS uptake increases, monitoring and tracking screening outcomes in clinical practice settings is key to high-quality screening and success,” the investigators noted. Large studies such as the NLST and the Dutch-Belgian Lung-Cancer Screening Trial have shown that LDCT lung cancer screening reduces mortality from the disease. But how much clinical trial success “translates to routine clinical practice remains uncertain,” Lafata and colleagues explained. To address the knowledge gap, the team conducted a five-year assessment of Duke’s LCS program, evaluating the frequency, type, and lung cancer stage in an LCS population and any association between patient characteristics and the Lung-RADS metric with disease diagnosis. The study included 3,326 patients who underwent 5,150 LCS exams between January 2015 and June 2020. The investigators tracked participants’ sociodemographic characteristics; Lung-RADS scores; incidence of pathology-proven lung cancers; and tumor characteristics using Duke...
Source: AuntMinnie.com Headlines - Category: Radiology Authors: Tags: CT Chest Radiology Source Type: news